US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

1.530 -0.080 (-4.97%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Century Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024 ↗
While not on everyone’s radar, these enticing entities just might deliver the goods. 
Via InvestorPlace
News headline image
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data ↗
IN8bio (NASDAQ: INAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these... 
Via Benzinga
News headline image
Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December ↗
Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps &... 
Via Benzinga
Topics ETFs
News headline image
Recap: Century Therapeutics Q3 Earnings ↗
 
Via Benzinga
News headline image
Century Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Analyst Ratings for Century Therapeutics ↗
 
Via Benzinga
News headline image
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
Where Century Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential ↗
Although speculative ideas tend to be losers more so than winners, these 10-bagger penny stocks might tempt the gambler. 
Via InvestorPlace
News headline image
Harnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio's Innovative Approach ↗
Why Are Gamma-Delta T Cells Important In Fighting Cancer? 
Via Benzinga
News headline image
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023 ↗
 
Via Benzinga
News headline image
Workday To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday ↗
Truist Securities raised the price target for Church & Dwight Co., Inc. (NYSE: CHD) from $95 to $105. Truist Securities analyst Bill Chappell upgraded the stock from Hold to Buy. Church & Dwight shares... 
Via Benzinga
News headline image
These Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 Results ↗
Century Therapeutics, Inc. (NASDAQ: IPSC) reported weaker-than-expected second-quarter results. 
Via Benzinga
News headline image
Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces Leadership Changes
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at the AACR Annual Meeting 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Upcoming Investor Conferences
From Century Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >